Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
New data show promise in using liquid biopsies to tailor immunotherapy
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Real-world evidence has a place in cancer immunotherapy
However, some challenges still limit its implementation in clinical practice
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Immunotherapy combinations consolidate their place in the first-line treatment of unresectable hepatocellular carcinoma
Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function
Studies show two promising new immune-related targets in cancer
Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials